Israel’s BrainStorm Initiates Technology Transfer to City of Hope for NurOwn ALS Phase 3 Study

Margarida Azevedo, MSc avatar

by Margarida Azevedo, MSc |

Share this article:

Share article via email
NurOwn stem cells

BrainStorm Cell Therapeutics has begun training the cell manufacturing team at City of Hope’s Center for Biomedicine and Genetics to produce NurOwn adult stem cells for a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS).

Los Angeles-based City of Hope will be the clinical supplier of NurOwn stem cells for all U.S. medical centers participating in the study.

NurOwn uses a patient’s own mesenchymal stem cells (MSCs), isolates them the patient’s bone marrow, and expands and induces them to differentiate into NurOwn (MSC-NTF) cells. The cells with neuro-protective properties are then transplanted back into the patient. NurOwn spurs production of growth factors that help neurons survive — a critical step in treating neurodegenerative diseases such as ALS.

BrainStorm develops and commercializes NurOwn in partnership with Ramot, the business engagement unit of Israel’s Tel Aviv University.

Following completion of a Phase 2 clinical trial that showed that NurOwn was safe and well tolerated — and able to halt or reverse ALS progression — the U.S. Food and Drug Administration (FDA) gave BrainStorm permission to start a Phase 3 trial. The randomized, double-blind, placebo-controlled multi-dose Phase 3 clinical trial will be conducted at multiple U.S. and Israeli sites, with enrollment of patients starting later this year.

The FDA has accepted some components of the Phase 3 program protocol to support a Biologic License Application for NurOwn.

“City of Hope is one of the world’s pre-eminent cell product manufacturing centers,” Chaim Lebovits, president and CEO of BrainStorm, said in a  news release. “The transfer of our proprietary autologous cell production technology to City of Hope’s production team reflects the rapid progress we are making in preparing for our Phase 3 ALS clinical study and will ensure that we have adequate high-quality cell-production capacity in place when we begin the Phase 3 study.  We welcome them as a clinical partner and appreciate their commitment to the success of this important clinical program.”

Added Joseph Gold, manufacturing director at the Center for Biomedicine and Genetics: “BrainStorm’s NurOwn technology represents an innovative approach to treating ALS. City of Hope is excited to play a role in treating this devastating disease.”